Efficacy and Tolerability of a Probiotic Ointment

Inclusion Criteria Male and female pediatric patients aged 0.5 years to 15 years with Atopic Dermatitis.

SCORAD Index at D0 = 15 to 50, inclusive. In goodgeneral health as reported by the parent(s)/legal representative(s). Available for the full duration of the study and willing to comply with procedures.

Subjects whose parents or legal representative are willing to sign the informed consent.

Exclusion Criteria Use of phototherapy for atopic dermatitis. Use of systemic corticosteroids within 2 weeks prior to the study. Use of Immunosuppressive or cytostatic drugs within 1 months prior to the study.

Use of antibiotics (topical and systemic) within 15 days prior to the start of the study.

Subjects who are treated with vitamin A-derived compounds or other topical medications for acne in the experimental area during the 30 days prior to the start of the study.

History of sensitivity to the study products, or its components. History or evidence of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis).

Subjects with active infection in atopic dermatitis areas requiring antibiotics, antifungals, or antiviral agents within 7 days before baseline participation in any study that would interfere with the current study.

Fever (temperature> 37.5 °C axillary or equivalent) during 48 hours prior the start of the study.

Pathologies associated with immunodeficiency or cancer processes. Any concurrent dermatologic or medical conditions that may interfere with the investigators ability to assess the subject's response to the study drug or require the continued use of topical corticosteroids.

Subjects who have received the schedule MMR vaccination during the study period or have received the last dose within three weeks prior the start of the study.

Subjects who participates in any study that would interfere with the current study.